Kornimate/medical-research-clean huggingface dataset:
upper extremity proprioceptive neuromuscular facilitation and chest expansion exercises in cerebral palsy

Conditions: Cerebral Palsy

Summary: thoracic mobility is the mobility of the thoracic spine, and the rib cage is often measured by the degree of thorax expansion during breathing. thoracic mobility is affected by many reasons, such as breathing mechanics, muscle stiffness, a sedentary lifestyle, and poor posture. the risk of respiratory illness should be assessed in all individuals with cerebral palsy. poor mobility of the thoracic will lead to limited breathing capacity and difficulty in daily life activities. increasing thoracic mobility enhances dynamic alignment and functional movement. proprioceptive neuromuscular facilitation (pnf) of upper extremity and chest expansion exercise can improve thoracic mobility. in this method, a physiotherapeutic approach is used in muscle strengthening, lengthening, and endurance training. the study aims to analyze the effect of an upper limb training program based on pnf techniques and chest expansion exercises on the thoracic mobility of a cerebral palsy patient.

the current study will be a randomized control trial; data will be collected from the lahore garrison institute of special education. the study will include 14 patients who are equally divided into two groups and randomly allocated. inclusion criteria for the study will be either gender of cp patients at gross motor function classification system level i to iii, who had no orthopedic surgery in the last 6 months and have a diagnosis of cp by doctors. patients with scoliosis and any acute or current respiratory infection or other respiratory conditions, such as asthma or influenza, will be excluded from the study. one experimental group will perform upper extremity pnf combined with elastic resistance bands; the other group will perform chest expansion exercises, which are upper extremity flexion, abduction, and external rotation exercises with an elastic band. the outcomes to be analyzed will be thoracic mobility. data collection will be done before and after the intervention. tools used for data collection will be brompton bpat breathing pattern assessment tool (bpat) and chest cirtometry. data will be analyzed through spss version 23.00.

Eligibility criteria:
inclusion criteria: * gross motor function classification system level of i to iii. * bpat score ≥ 4. * either gender will be included exclusion criteria: * recent chest infection. * children who are hospitalized * scoliosis * no orthopedic surgery in last 6 months

Keywords: chest cirtometry cerebral palsy thoracic mobility pnf of upper extremity chest expansion bpat
the effect of probiotics on bowel function restoration after ileostomy closure in patients with rectal cancer

Conditions: Rectal Cancer

Summary: the study will investigate whether probiotics(cjlp243) given just before and after ileostomy repair operation in patient with rectal cancer improve a bowel function.


Eligibility criteria:
inclusion criteria: * age: 20-75 * with rectal cancer * s/p low anterior resection (double stapled anastomosis) exclusion criteria: * metastatic cancer * pregnancy * valvular heart disease * s/p intersphincteric resection (index surgery) * h/o anastomotic leakage (index surgery) * medically unfit (cardiopulmonary dysfunction, sepsis etc)
longitudinal study of crs/hipec for peritoneal carcinomatoses

Conditions: Peritoneal Carcinomatosis

Summary: longitudinal study of the effect of cytoreductive surgery and hipec in patients with peritoneal carcinomatoses

cross-sectional and longitudinal analysis of cellular immune responses in the context of disease outcome. cross-sectional and longitudinal analysis of the microbiome in the context of disease outcome. analysis of renal function with respect of different hipec regimens identification of clinical surrogate parameters for outcome.

Eligibility criteria:
inclusion criteria: * suspicious peritoneal carcinomatosis exclusion criteria: * \<18 years

Keywords: crs hipec cellular immune response microbiomes
atrial fibrillation trial to eliminate risk-factors

Conditions: Atrial Fibrillation

Summary: the goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. the main questions it aims to answer are: 1. to understand the baseline characteristics and to explore the occult risk factors of the patients with af; 2. to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with af. participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

atrial fibrillation (af) is a heart condition that potentially leads to heart failure and ischemic stroke. the prevalence of af is increasing due to aging population and improved treatment in other cardiovascular field. this study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

Eligibility criteria:
inclusion criteria: * at least 18 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram exclusion criteria: 1. unable to complete the initial assessment and cooperate with the tracker 2. those who refuse to sign the subject's consent

Keywords: atrial fibrillation
treatment outcomes of react for pnes

Conditions: Convulsion, Non-Epileptic

Summary: this research study is examining the effects of retraining and control therapy (react; an intervention focused on changing behaviors and thoughts) for psychogenic non-epileptic seizures (pnes, episodes resembling epileptic seizures but with no medical explanation). participants engage in 8 individual therapy sessions consisting of either cognitive behavioral therapy or supportive therapy. healthy control participants also complete pre-questionnaires and two computer tasks.

participants come to our laboratory for a total of 11 sessions. during the initial visit, participants complete several questionnaires assessing demographics, personality style, relationships with friends and family, as well as past and current pnes symptoms. they also completed two computer tasks: the magic and turbulence task and a modified stroop task. participants must provide eeg results indicating a diagnosis of psychogenic non-epileptic seizures. participants receive a pnes diary to record all episodes during the course of the study. they are randomly assigned to either receive react for pnes or supportive therapy, and they return 8 times over the next 8 weeks for therapy sessions. if randomized to react, participants and a family member learn how to change behaviors and thoughts to address pnes. if randomized to supportive therapy, they discuss stressors and how they relate to the pnes. procedures are the same for each therapy group. the first therapy session lasts approximately 90 minutes. all subsequent sessions last about one hour. after completing the 8 therapy sessions participants return one week later for a follow-up visit lasting approximately one hour. this visit consists of answering several questionnaires and an interview about current pnes symptoms. participants return two months later for a final follow-up visit similar to the one week follow up visit. lastly, participants and their parent are called 1 year after completing treatment and are asked to report pnes frequency over the last 30 days. they are also asked if they think react was helpful, and if so, what the most helpful part of react was. healthy controls are matched to participants with pnes based on age (+ or - 1 year), gender, race and family income. they come for 1 laboratory visit to complete the initial visit questionnaires and computer tasks.

Eligibility criteria:
inclusion criteria: * 9-18 years old. * diagnosis of psychogenic non-epileptic seizures by a medical doctor using video/eeg. * family member (parent if a minor) willing to participate and that the subject with pnes chooses. exclusion criteria: * substance use. * psychosis. * severe intellectual disability * diagnosis of epilepsy is acceptable as long as patient's neurologist confirms that epileptic seizures are currently under control. healthy controls are matched on age (+ or - 1 year), sex, race and family income and can have no psychiatric or medical diagnosis.
metastatic gastric cancer ffcd 03-07

Conditions: Stomach Cancer; Neoplasm Metastasis

Summary: the purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.

to compare the effectiveness of two different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.

Eligibility criteria:
inclusion criteria: * age = 18 years old * patients carrying a adenocarcinoma of the stomach or cardia histologically proven * locally advanced tumour which may not be treated surgically or metastatic tumour * the patients having a stenosante tumour responsible for a disphagy had to have a tumoral ablation or a prosthesis or a probe of food, * measurable lesions according to criteria recist (specify measurement by spiral scanner of largest diameter of with less the one lesion of size higher than 1 cm) or appraisable but nonmeasurable (lesions \< 1 cm, ascite, pleural effusion...) * general state who \< 2 * absence of insufficiency cardiac or coronary symptomatic * absence of previous chemotherapy other that auxiliary stopped since more than 6 months * filled questionnaires qlq c30 and sto-22 * pnn = 1500/mm3, haemoglobin ≥ 10g/dl, plates= 100 000/mm3 * creatinin ≤ 110 micromol/l * bilirubin ≤ 35 micromol/l exclusion criteria: * disphagy or intestinal obstruction incompatible with a treatment per os or by a probe of food * pregnant or nursing woman * previous of cardiac toxicity to the 5fu or to the anthracyclines * radiotherapy less than 3 weeks before inclusion, whatever the site * other evolutionary cancer threatening the short-term life * metastasis cerebral or méningée known (without obligation to seek it) * impossibility of regular follow-up for psychological, social, family or geographical reasons

Keywords: chemotherapy stomach cancer metastatic capecitabine irinotecan
accelerated transcranial magnetic stimulation for people with schizophrenia treated with clozapine

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: in this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (itbs) can augment neurocognition in individuals who receive treatment with clozapine. following a baseline evaluation and magnetic resonance imaging (mri), participants will undergo a session of itbs +mri and session of sham delivery + mri. the order for these sessions will be blinded and randomized. the investigators predict that accelerated itbs will enhance neurocognition relative to sham delivery.


Eligibility criteria:
inclusion criteria: 1. a current diagnostic and statistical manual of mental disorders 5 (dsm 5)-defined diagnosis of schizophrenia or schizoaffective disorder 2. age 18-50 years 3. at least 4 months of clozapine treatment 4. history of at least 2 failed antipsychotic trials 5. competency and willingness to sign informed consent 6. a clinically optimized dosage of clozapine, unchanged for at least 1 month, with a minimum of 150 mg/day exclusion criteria: 1. serious neurologic or medical condition/treatment that impacts the brain 2. a significant risk of suicidal or homicidal behavior 3. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent 4. pregnancy or postpartum (\<6 weeks after delivery or miscarriage) 5. history of treatment with electroconvulsive therapy 6. contraindications for magnetic resonance imaging (e.g., a pacemaker) 7. structured clinical interview for diagnostic and statistical manual of mental disorders 5 (dsm 5)-verified moderate or severe substance use disorder, including alcohol use disorder 8. seizure disorder or prior history of seizures on clozapine 9. patients taking both bupropion and clozapine 10. prior issues with intermittent theta burst stimulation/transcranial magnetic stimulation administration concomitant treatment with serotonin and norepinephrine reuptake inhibitors will be examined on a case-by-case basis.
registry to monitor the susceptibility to aztreonam of pseudomonas aeruginosa isolates from cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: this is a prospective, longitudinal, 5-year study that will enroll participants from the existing cystic fibrosis foundation (cff) patient registry. each enrolled participant will provide samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.


Eligibility criteria:
key inclusion criteria: subjects must meet all of the following inclusion criteria to be eligible for participation in this study. * current participant or willingness to participate in the cff patient registry database * ≥ 6 years of age * subject has cf as diagnosed by one of the following * documented sweat chloride ≥ 60 meq/l by quantitative pilocarpine iontophoresis test, or * two well-characterized genetic mutations in the cftr gene, or * abnormal nasal potential difference (npd) and accompanying clinical characteristics consistent with cf. for subjects who lack documentation of either a positive sweat chloride test or an abnormal npd, and who have only one well-characterized genetic mutation of the cftr gene, the diagnosis of cf is determined by the investigator. * fev1 ≥ 25% predicted and ≤ 90% predicted. * ≥ 2 lower respiratory tract cultures positive for pa with results documented in the subject's medical history. * subject must be able to provide written informed consent/assent prior to any study related procedure; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure. key exclusion criteria: subjects who meet the following exclusion criterion are not to be enrolled in this study. • any serious active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject assessment. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: cystic fibrosis pa pseudomonas aeruginosa cf aztreonam
zk283197 for treatment of vasomotor symptoms

Conditions: Vasomotor System

Summary: the primary goal of the planned study is to investigate the efficacy and safety of zk 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes. in order to be able to assess the efficacy of the test substance, this is compared with the efficacy of 1 mg estradiol and placebo. the comparator estradiol is a certified hormone preparation, which is already used for the treatment of hot flushes as standard treatment. after passing the screening, volunteers will start with a run-in phase followed by a 8 weeks treatment and a follow-up phase. 112 postmenopausal women with hot flushes and without relevant prior diseases will participate in three european countries (2 study sites in germany, 1 study site in great britain and 1 study site in the netherlands) in this study.


Eligibility criteria:
inclusion criteria: * women with at least 35 moderate to severe hot flushes in seven consecutive days * body mass index (bmi) : 20 - 30 kg/m² (inclusive) * postmenopausal status exclusion criteria: * contraindication for use for hormonal therapy * prior hysterectomy * hormonal therapy or intrauterine hormone releasing device within 4 weeks prior to study entry or any long-acting injectable or implant up to 6 months prior to study entry * repeated intake of medications affecting study aim

Keywords: hot flushes therapy of hot flushes 17ß-estradiol (e2) hormone replacement therapy
reaction time and postural control in individuals with cystic fibrosis and bronchiectasis

Conditions: Cystic Fibrosis; Bronchiectasis

Summary: the aim of this study is to evaluate the reaction time and postural control and to investigate the relationship between reaction time, exercise capacity, muscle oxygenation and balance in children with cystic fibrosis (cf) and non-cf bronchiectasis. 40 patients including 20 cf patients and 20 non-cf bronchiectasis and 20 healthy individuals will be included in this study. demographic and physical characteristics' will be recorded. lung function testing will be performed. balance will be assessed using functional reach test, exercise capacity was measured using the incremental shuttle walking test and reaction time will be assessed using ''fitlight trainertm''. heart rate, respiratory rate, oxygen saturation, muscle oxygenation, dyspnea and fatigue perception will be measured before and after exercise test and reaction time measurement.


Eligibility criteria:
inclusion criteria: * children diagnosed with bronchiectasis and cystic fibrosis at 6-18 years old age for the bronchiectasis and cystic fibrosis groups respectively * healthy children at 6-18 years old age for the healthy group. * stable medical condition (free from the acute exacerbation) * children who have not participated in the planned exercise training program in the last 3 months * compliance with the tests exclusion criteria: * children who have a physical problems that limit the application of the tests * acute infection or unstable medical status

Keywords: postural control reaction time cystic fibrosis bronchiectasis
efficacy study of homeopathic medicines in treatment of allergic rhinitis and/or induced bronchial asthma

Conditions: Rhinitis; Allergic, With Asthma

Summary: the purpose of this study is to test whether individualized homeopathic medicines can produce any significant effect beyond placebo in treatment of allergic rhinitis and/or induced bronchial asthma

a prospective, single-blind (subject), randomized, placebo-controlled, parallel group, interventional clinical trial is being conducted on 100 participants (subjects 50, control 50) suffering from allergic rhinitis and/or induced bronchial asthma since march 1, 2012 at mahesh bhattacharyya homeopathic medical college and hospital, government of west bengal. this trial is aimed at exploring the efficacy of homeopathic medicines in comparison with placebo in reducing serum interleukin 10, 13 and immunoglobulin e measured at timeline of 1 year of treatment and absolute eosinophil count every 4 months up to 1 year. matching for independent and consequent variables will be done to test for bias. parametric or non-parametric tests will be employed as per distribution of data at the end of the trial.

Eligibility criteria:
inclusion criteria: * age between 5 and 65 years * both sexes * atopic: reactive to allergens with positive skin prick test (spt) results and/or eosinophilia * more than 1 year history of allergic rhinitis and/or induced bronchial asthma exclusion criteria: * nasal abnormalities causing obstruction, e.g. nasal polyp(s), deviated septum etc. * previous homoeopathic immunotherapy for allergic rhinitis * allergen avoidance in past 6 weeks * away from usual environment for more than 1 week during trial * severe asthma cases as detected clinically * respiratory infection * severe concomitant disease * pregnancy, breast feeding, or likelihood of pregnancy * oral or parenteral steroids and/or decongestant in past 6 months * conventional desensitization in past 3 months

Keywords: interleukin immunoglobulin homeopathy allergic rhinitis asthma
m4c nutraceutical intervention human health effects pilot

Conditions: General Health and Wellness; Energy and Vitality; Cognitive Function and Mental Health; Weight Management; Digestive Health; Exercise Tolerance; Cardiovascular Health; Bone and Joint Health; Skin, Hair, and Nail Health; Immune Support; Sports Performance and Recovery; Sleep and Relaxation; Obesity; Anti Inflammatory

Summary: this 3 month pilot study will be an unblinded, convenience sampling, nutraceutical intervention trial. twenty fasted subjects will undergo a baseline health assessment via a questionnaire, baseline clinical chemistries, blood lipids, dexa and impedence testing (to identify bone mineral density and body muscle/fat/water composition), and metabolite/novel biomarker testing through whole capillary blood, saliva, and urine collections. assessments will be repeated every month (3 times after initial assessment) to cover a 3 month period. all measurements from each visit will be compared with baseline using paired t-tests or chi square testing depending on variable. power analyses are not included due to the pilot nature of the study. this pilot study will provide the necessary variability estimates for future trials.

the purpose of this study is to explore potential positive human health effects of a proprietary nutraceutical formulation known as m4c. the impetus for m4c came from dr. mcgraw's attempt to alleviate the chronic inflammation a family member was experiencing through a non-invasive, natural, nutraceutical approach. anecdotal findings of m4c show an antiinflammatory effect (observed in the presence of inflammatory conditions and after traumatic injury such as a sprain or fall), improved metabolic, gastrointestinal, and mental health, as well as enhanced exercise response and recovery. in this study the investigators will examine whether supplementation with m4c is associated with any changes in lipids, clinical chemistries, body composition, questionnaire covariates, metabolites/novel suspected lipopeptides, hemoglobin a1c, or bone mineral density.

Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * amputation * blood clotting disorder * metal implants or implanted electrical device(s) * known acute or chronic illness; gastrointestinal, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension * inability to fast i.e. low blood sugar * pregnant or may be pregnant during the course of the study * amino acid metabolizing disorder i.e. phenylketonuria * severe edema * did not pass screening criteria as determined by mri facility * allergies/intolerance to any nutraceutical ingredients: amino acids, vitamins, minerals, tapioca starch, sunflower lecithin, stevia, limes or fatty acids like docosahexaenoic acid

Keywords: general health and wellness energy and vitality cognitive function and mental health weight management digestive health exercise tolerance cardiovascular health bone and joint health skin, hair, and nail health immune support sports performance and recovery sleep and relaxation obesity anti inflammatory
effects of progressive resistance exercise training on endurance and functional mobility in children with spina bifida

Conditions: Spina Bifida

Summary: in this research the effects of progressive resistance exercise training on endurance and functional mobility in children with spina bifida are assessed.


Eligibility criteria:
inclusion criteria: * 8 to 16 year. * male and female both are included. * lower extremity weakness (less than 2). * knee and hip flexion contractures exclusion criteria: * bowel and bladder dysfunction. * children having absent tone. * children having bone fracture

Keywords: resistance exercise endurance functional mobility